Adipotide (also known as FTPP or Prohibitin-TP01) is a first-in-class peptidomimetic developed by Arrowhead Research Corporation and MD Anderson Cancer Center. It comprises two functional domains:
- CKGGRAKDC– a homing motif that selectively binds prohibitin on the surface of white-fat blood-vessel endothelium
- D(KLAKLAK)₂– a cationic, amphipathic proapoptotic sequence that disrupts mitochondrial membranes
After binding prohibitin, Adipotide is internalized and triggers rapid apoptosis of white-adipose vasculature, resulting in profound fat loss (up to 30% body weight in 28 days in obese rhesus monkeys). Originally advanced to Phase I for cancer-related cachexia, development was halted due to renal toxicity concerns at high doses. This research-grade lyophilized peptide is synthesized under strict quality controls and provided with full analytical documentation, making it the benchmark tool for selective adipocyte ablation and obesity research.
Key Scientific
- High-purity Adipotide (≥ 98% by HPLC/MS, TFA salt form)
- Verified dual-domain sequence: CKGGRAKDC-GG-D(KLAKLAK)₂ (cyclic via disulfide)
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for prohibitin targeting, adipose vasculature apoptosis, and rapid fat-loss models
Research-Referenced Attributes (Based on scientific literature; not intended as therapeutic claims.)
- Selective apoptosis of white-fat endothelium → 30% body weight loss in 28 days (obese monkeys)
- 70–90% reduction in abdominal fat volume with minimal muscle loss
- Improves insulin sensitivity and reverses type 2 diabetes markers in preclinical models
- No effect on lean tissue vasculature (spares brown fat, muscle, organs)
- Rapid onset (weight loss visible within 7–10 days)
- Valuable in extreme obesity, metabolic syndrome, and cancer-cachexia research
Why Researchers Choose Nationwide Peptides Adipotide
- Exact clinical-sequence match used in original MD Anderson / Arrowhead studies
- Highest documented fat-specific apoptosis potency among research suppliers
- Transparent analytical data (HPLC >98%, MS confirmation of both domains)
- Trusted by obesity, vascular biology, and oncology laboratories
- Competitive research pricing with bulk options
